PAI-1与代谢综合征

Plasminogen activator inhibitor-1 and metabolic syndrome

血浆纤溶酶原激活物抑制剂(PAI)-1是纤溶系统的主要调控因子。近年研究发现,PAI- 1的升高是代谢综合征的一个核心特征,与肥胖、胰岛素抵抗、2型糖尿病、心血管疾病、脂代谢紊乱和高血压等密切相关,甚至可能影响内脏脂肪的蓄积。因此,对PAI—1的直接抑制不仅为降低心血管危险因素提供新的治疗策略,也对治疗肥胖、胰岛素抵抗及2型糖尿病等有益。

Plasminogen activator inhibitor- 1 （PAl- 1 ） is the main regulator of the fibrinolytic system. Recent researches find that the elevation of PAI-1 level is a core feature of metabolic syndrome, and has a close relationship with obesity, insulin resistance, type 2 diabetes, cardiovascular diseases, dyslipidemia and hypertension, and even may influence the accumulation of visceral fat. Therefore, direct inhibition of PAI-1 might not only provide a new therapeutic strategy for reducing eardiovascular risk, but also have beneficial effects on obesity, insulin resistance and type 2 diabetes.